Complix Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 23
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2M
Latest Deal Amount
  • Investors
  • 12

Complix General Information

Description

Operator of a biopharmaceutical company intended to target intractable or challenging disease targets. The company is developing a transformative pipeline of Alphabody therapeutics primarily addressing intracellular disease targets that play an important role in cancer, autoimmunity, and viral diseases, enabling patients to overcome the limitations of conventional antibodies and small molecules through combining the specific potency of biologics with the cell-penetrating capacity and stability of small molecules.

Contact Information

Website
www.complix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • BioVille
  • Agoralaan building A-bis
  • 3590 Diepenbeek
  • Belgium
+32 09 000 00 00

Complix Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Complix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 07-Oct-2020 $2M 000.00 Completed Generating Revenue
9. Later Stage VC 01-Jan-2020 000.00 Completed Generating Revenue
8. Later Stage VC (Series D) 05-Aug-2019 000.00 000.00 00000 Completed Generating Revenue
7. Secondary Transaction - Private 000.00 Completed Generating Revenue
6. Later Stage VC 30-Jun-2017 00.00 000.00 0000 Completed Generating Revenue
5. Later Stage VC (Series B) 13-Mar-2015 000.00 000.00 0000 Completed Startup
4. Grant 30-Oct-2012 00.000 00.00 Completed Startup
3. Early Stage VC (Series A) 13-Jan-2011 00.00 00.00 000.00 Completed Startup
2. Grant 12-Dec-2010 $2.14M Completed Startup
1. Seed Round 01-Jan-2008 Completed Startup
To view Complix’s complete valuation and funding history, request access »

Complix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.00 00.00 00 00.00 0.000
Series D 00,000,000 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.00 00.00 00 00.00 00.000
Series B 19,512,082 $0.69 $0.69 1x $0.69 11.96%
Series A 11,323,198 $0.69 $0.69 1x $0.69 6.94%
To view Complix’s complete cap table history, request access »

Complix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical company intended to target intractable or challenging disease targets. The company is de
Drug Discovery
Diepenbeek, Belgium
23 As of 2021
000.00
0000000000 000.00

00000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000 000000000
San Francisco, CA
00 As of 0000
0000
0000000 0000 0000

00000000

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Complix Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prosetta Biosciences Private Equity-Backed San Francisco, CA 00 0000 0000000 0000 0000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
000000 00000000000 Venture Capital-Backed Lexington, MA 00 00000 00000000 00000
00000000 Venture Capital-Backed Heidelberg, Germany 00 000.00 0000000000 000.00
You’re viewing 5 of 29 competitors. Get the full list »

Complix Executive Team (4)

Name Title Board Seat Contact Info
Mark Vaeck Ph.D Co-Founder, Chief Executive Officer & Board Member
Ignace Lasters Ph.D Co-Founder & Chief Technology Officer
Thore Hettmann Ph.D Head, Therapeutic and Business Development
You’re viewing 3 of 4 executive team members. Get the full list »

Complix Board Members (14)

Name Representing Role Since
Gaston Matthyssens Ph.D Vesalius Biocapital Partners Board Member 000 0000
Gilles Nobécourt Andera Partners Board Member 000 0000
Hans Schikan Self Chairman 000 0000
Johan Cardoen Ph.D Self Board Member 000 0000
Mark Vaeck Ph.D Complix Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Complix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Complix Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Vlaams Agentschap Innoveren en Ondernemen Endowment Limited Partner Minority 000 0000 000000 0
Andera Partners PE/Buyout Minority 000 0000 000000 0
Baekeland Fonds II Corporation Minority 000 0000 000000 0
Biotech Fund Flanders Venture Capital Minority 000 0000 000000 0
Gimv PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »